Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis

Introduction Familial Mediterranean fever(FMF) is an autoinflammatory disease characterized by interleukin (IL)-1 overproduction. Colchicineis the mainstay drug in the treatment of FMF; however, a minority of patients do not respond despite the highest tolerated doses. We aimed to share our experience with canakinumab, a human monoclonal antibody against IL-1β, in pediatric FMF patients.